Key Highlights
- 39.3 percent was the reported August 10, 2026 plunge for Quanterix (NASDAQ:QTRX) to USD 2.45 after management cut its full-year Revenue outlook and pushed cash-flow breakeven out to 2027.
- USD 3.64 was the reported October 2, 2026 close for Quanterix (NASDAQ:QTRX), roughly 48.6 percent above the August low, simple arithmetic on two published prices, with a Market Value near USD 171.5 million.
- September 25, 2026 was when Quanterix (NASDAQ:QTRX) moved its PhenoCode 2.0 molecular barcoding kit from early access to full commercial release, with two panels scheduled to ship in the fourth quarter.
- USD 142 million to USD 148 million is the revised 2026 revenue range for Quanterix (NASDAQ:QTRX), down from USD 169 million to USD 173 million, so execution remains the central risk.
What the Published Data Show
Published market data put Quanterix (NASDAQ:QTRX) at USD 3.64 at the October 2, 2026 close, and a stub circulating for this topic reported a 6.74 percent gain that day. The stub's headline claim of a 7.1 percent decline could not be matched to any verified session, and no October 5 or October 6 price data were found. The more verifiable catalyst is the September 25, 2026 commercial release of PhenoCode 2.0, a molecular barcoding kit that lets researchers barcode antibodies for high-plex spatial biology assays. Quanterix also said a TIME panel for tumor immune profiling and a high-plex antibody-drug conjugate panel would ship in the fourth quarter, and that its lab services unit now accepts custom panel requests.
Context: Guidance Reset and Cash
The rebound starts from a low base. On August 10, 2026, Quanterix reported second-quarter revenue up 34 percent to USD 32.9 million but an adjusted EBITDA loss of USD 10.0 million, and cut 2026 revenue guidance to USD 142 million to USD 148 million. Adjusted gross Margin guidance fell to 48 percent to 50 percent, and year-end cash was guided to about USD 80 million, down USD 20 million. The shares fell 39.3 percent to USD 2.45. Chief executive Everett Cunningham cited execution challenges and market softness. A new product helps only if it converts into instrument and consumable orders, which are the revenue lines the guidance cut targeted. Quanterix also named Yuri Fesko chief medical officer in mid-September.
Risks, Peers and What to Watch
Quanterix (NASDAQ:QTRX) is a small, loss-making tools company, so moves of several percent in a day are common and Volume can be thin. Risks include further guidance cuts, cash burn before the targeted 2027 breakeven, weak academic and biopharma research budgets and execution on spatial biology after the integration of Akoya. Reported peer moves in the stub, such as Nautilus Biotechnology up 4.3 percent, were not independently verified. An upgrade to Hold from Wall Street Zen on September 19 is a quantitative rating, not a fundamental catalyst. The next dated checkpoint is the third-quarter Earnings report, expected in November 2026, with the exact date not confirmed.
Where Things Stand
Quanterix (NASDAQ:QTRX) is rebounding because the shares fell hard in August and have recovered on product news, with PhenoCode 2.0 now commercial and panels due in the fourth quarter. The recovery is partial: USD 3.64 is still well below levels before the guidance cut, and no company announcement explaining an October 5 or October 6 move was found. Investors will watch order trends, cash against the USD 80 million year-end guide, and the November earnings report.






Please wait processing your request...